$RUBY Rubius Therapeutics, Inc. Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Rubius Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Rubius Therapeutics, Inc.. Insider overview, share value development, latest insider transactions and email notifications about new events in Rubius Therapeutics, Inc. for free.
IRS Number: 042688109
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Trading Symbol: RUBY
Company Address: 399 BINNEY STREET, SUITE 300 CAMBRIDGE 02139
Phone number: 617-679-9600
Former name: VL26, Inc.
Rubius Therapeutics, Inc. Latest Insider Transactions
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13 2021 | RUBY | Rubius Therapeutic ... | Epstein David R | Director | Option Exercise | A | 23.25 | 27,919 | 649,117 | 27,919 | |
| May 13 2021 | RUBY | Rubius Therapeutic ... | Symonds Jonathan | Director | Option Exercise | A | 23.25 | 25,000 | 581,250 | 25,000 | |
| May 13 2021 | RUBY | Rubius Therapeutic ... | AFEYAN NOUBAR | Director | Option Exercise | A | 23.25 | 25,000 | 581,250 | 25,000 | |
| May 13 2021 | RUBY | Rubius Therapeutic ... | Sohn Catherine A. | Director | Option Exercise | A | 23.25 | 25,000 | 581,250 | 25,000 | |
| May 13 2021 | RUBY | Rubius Therapeutic ... | Rosenblatt Michael | Director | Option Exercise | A | 23.25 | 25,000 | 581,250 | 25,000 | |
| May 13 2021 | RUBY | Rubius Therapeutic ... | Cuss Francis M | Director | Option Exercise | A | 23.25 | 25,000 | 581,250 | 25,000 | |
| May 13 2021 | RUBY | Rubius Therapeutic ... | Holles Natalie C. | Director | Option Exercise | A | 23.25 | 25,000 | 581,250 | 25,000 | |
| May 13 2021 | RUBY | Rubius Therapeutic ... | Prener Anne | Director | Option Exercise | A | 23.25 | 25,000 | 581,250 | 25,000 | |
| Mar 23 2021 | RUBY | Rubius Therapeutic ... | Flagship Ventures Fund IV Gene ... | 10% Owner | Buy | P | 29.00 | 70,000 | 2,030,000 | 2,633,703 | 2.6 M to 2.6 M (+2.73 %) |
| Mar 23 2021 | RUBY | Rubius Therapeutic ... | Flagship Ventures Fund IV Gene ... | 10% Owner | Buy | P | 29.00 | 70,000 | 2,030,000 | 5,859,414 | 5.8 M to 5.9 M (+1.21 %) |
| Mar 23 2021 | RUBY | Rubius Therapeutic ... | Flagship Ventures Fund IV Gene ... | 10% Owner | Buy | P | 29.00 | 70,000 | 2,030,000 | 15,393,593 | 15.3 M to 15.4 M (+0.46 %) |
| Mar 15 2021 | RUBY | Rubius Therapeutic ... | Keson-Brookes Maiken | CLO & Corp. Secreta ... | Option Exercise | M | 7.70 | 25,000 | 192,500 | 225,000 | |
| Mar 15 2021 | RUBY | Rubius Therapeutic ... | Keson-Brookes Maiken | CLO & Corp. Secreta ... | Sell | S | 20.24 | 25,000 | 505,965 | 0 | 25 K to 0 (-100.00 %) |
| Mar 15 2021 | RUBY | Rubius Therapeutic ... | Keson-Brookes Maiken | CLO & Corp. Secreta ... | Buy | M | 7.70 | 25,000 | 192,500 | 25,000 | 0 to 25 K |
| Feb 16 2021 | RUBY | Rubius Therapeutic ... | Epstein David R | Director | Sell | S | 14.93 | 26,704 | 398,560 | 4,690,012 | 4.7 M to 4.7 M (-0.57 %) |